Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM

ASCO 2024

31 May - 4 Jun 2024

Published: 1 Jun 2024

Views: 30

Rating:

Save

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Dr Maria-Victoria Mateos speaks to ecancer at ASCO 2024 about the results from the subgroup analysis for the phase 3 DREAMM-7 study.

This trial evaluated belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma.

In the previous analysis, BVd demonstrated a statistically significant and clinically meaningful progression-free survival benefit vs standard-of-care DVd.

Dr Mateos reports that there was improvement of 23 months in patients with RRMM and over 1 prior line of treatment.

Related Videos

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival...

Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )

More from ecancer